Pope Leo XIV urged greater international efforts to stop the Ebola outbreak in the Democratic Republic of Congo, as the death toll surpassed 2,600 and response efforts faced disruptions from violence and funding shortfalls. The pontiff called for stronger global reaction and community involvement to address the ongoing health crisis.
Reports indicate that a vaccine for the Ebola virus could be developed and ready for use by the end of the current year, offering hope in the fight against the deadly disease.
The Democratic Republic of Congo has received its initial shipment of Ebola vaccine doses, as the country continues to battle an outbreak that has claimed over 2,500 lives.
An Ebola vaccine trial is set to begin in the Democratic Republic of Congo, as the WHO issues a warning about the rapid speed of infections, with half of the 2,500 recorded deaths occurring recently.
The Democratic Republic of Congo is set to receive 70,000 doses of the Ervebo vaccine to combat a surge in Ebola infections. This delivery aims to bolster the country's efforts against the escalating health crisis.
Companies that developed COVID-19 vaccines at record speed are now making significant progress on a vaccine for the current Ebola variant in DR Congo, potentially setting a new world record for vaccine development.
The Ebola outbreak in the Democratic Republic of Congo has surpassed 2,000 deaths, with the virus continuing to spread rapidly and posing significant challenges to containment efforts. The World Health Organization notes the virus is outpacing current responses, leading to a near doubling of maternal mortality in affected areas.
The World Health Organization has recommended a clinical trial for an Ebola vaccine, following preliminary animal study data suggesting it may offer cross-protection and reduce deaths from the Bundibugyo virus.
A 19-year-old French student was fined $465 in Singapore for licking a straw from a drink dispenser and returning it, an act that went viral online. The court showed no leniency despite his apologies.
The University of Oxford has officially launched the first human trial for a vaccine specifically targeting the Bundibugyo strain of Ebola, marking a critical step in global efforts to combat the deadly virus. This trial represents a significant advancement in developing defenses against this particular strain.
Oxford University has launched the first human trial of a new Bundibugyo Ebola vaccine, as the outbreak continues to spread in the Democratic Republic of Congo. This trial is a critical step in combating the deadly virus.
Scientists, pharmaceutical companies, and funding bodies worldwide are actively working to develop and safely test new vaccines and treatments in response to ongoing Ebola outbreaks.
A global effort is intensifying to develop a new vaccine to combat the ongoing Ebola crisis. Researchers and health organizations worldwide are working to accelerate the development and deployment of effective preventative measures.
An Al Jazeera report examines the current state of Ebola vaccine research, discussing the various vaccines under development and their potential timelines for readiness.
A global race is underway to develop vaccines for various Ebola species, with IAVI, Moderna, and the University of Oxford actively working on new candidates amid increasing fears of potential outbreaks.
IAVI, Moderna, and the University of Oxford are actively working on developing three new Ebola vaccines, spurred by increasing fears of potential outbreaks.
The World Health Organization has cautioned that an Ebola vaccine could take up to nine months to develop, as the death toll from the current outbreak continues to climb.
Efforts to develop an Oxford Ebola vaccine are accelerating in response to a surging outbreak in Congo, aiming to provide a crucial tool against the disease.
Chinese researchers have developed an Ebola vaccine using mRNA technology, similar to that used for Covid-19. Animal trials have shown the vaccine to be effective against the currently devastating Bundibugyo strain.
Scientists in the UK, including those at Oxford, are developing a new Ebola vaccine that could be ready for trials within a few months, leveraging breakthroughs from Covid vaccine development.
Scientists in the UK are developing a new Ebola vaccine that could be ready for use within a few months, offering a potential new tool in combating the deadly virus.
An angry crowd in the Democratic Republic of Congo set fire to an Ebola treatment center, fueled by growing tensions and disputes related to the ongoing outbreak. The incident occurred as the Ebola outbreak continued to spread in the region.
The World Health Organization stated that the current Ebola outbreak in the Democratic Republic of Congo likely began months ago and spread undetected, warning of its potential growth. WHO officials also indicated that an Ebola vaccine could take up to nine months to develop, while the UK pledged £20 million for containment efforts.
Scientists have developed an experimental vaccine that successfully protected mice against three species of Ebola, including the Bundibugyo strain. New studies reveal the Bundibugyo strain is less lethal than the Zaire strain, killing 30% to 40% of infected people, while the vaccine still requires human testing.
The Democratic Republic of Congo has received its first shipment of Ebola vaccines as the current outbreak continues to grow exponentially. This delivery aims to bolster efforts to control the spread of the deadly virus.
The Democratic Republic of Congo has received over 16,000 doses of the Ebola vaccine to combat an unprecedented and rapidly spreading outbreak. The arrival of the vaccines is a critical step in addressing the escalating health crisis in the country.
The Democratic Republic of Congo has received 70,000 doses of the Ervebo vaccine to combat the rapidly spreading Ebola outbreak. However, the World Health Organization noted that these doses are not approved for the specific Bundibugyo strain currently prevalent in the region.
The World Health Organization has recommended a Phase III trial for an Ebola vaccine specifically targeting the Bundibugyo virus. This recommendation comes as researchers develop vaccines and treatments for the ongoing outbreak in the Democratic Republic of the Congo.
WHO vaccine experts have recommended a full-scale human trial of the only existing approved Ebola vaccine, Ervebo, to assess its cross-protection against a deadly strain spreading in the Democratic Republic of Congo.
Moderna has received authorization to begin clinical trials in Canada for its Ebola vaccine. This vaccine targets a new strain of the virus that has caused numerous fatalities.
The first human trial for an experimental vaccine targeting the Bundibugyo strain of Ebola has commenced, with a volunteer in the UK receiving the initial dose. This development comes as Ebola cases in DR Congo continue to rise, reaching 2,905.
Oxford University has initiated the first human trial for a vaccine targeting the Bundibugyo strain of the Ebola virus, marking a significant step in vaccine development.
The Democratic Republic of Congo has reported over 700 confirmed Ebola cases and 149 deaths, as health workers struggle to contain the outbreak in camps due to growing distrust. The WHO warns of potential spread to new areas.
The Coalition for Epidemic Preparedness Innovations (CEPI) has invested $1.9 million to speed up the development of an Ebola vaccine. This initiative comes as the Bundibugyo outbreak has led to over 560 confirmed infections and more than 100 deaths.
Three vaccine candidates are being fast-tracked to combat a rare Ebola species spreading in Central Africa. Major organizations and companies are collaborating on this effort, despite logistical challenges.
Scientists are aiming to begin human trials for a new Ebola vaccine candidate against the deadly Ebola Bundibugyo strain within months, following a surge in funding.
The WHO Chief has stated that community trust is crucial for stopping the spread of a rare Ebola strain, as the outbreak continues to spread in Africa. This comes as global health funders fast-track three Ebola vaccines and Europe holds extraordinary talks on the virus.
The Africa CDC has stated that financial pledges for combating the Ebola outbreak have been nearly halved. Despite this, the agency aims to have an Ebola vaccine available by the end of 2026.
The Ebola outbreak in the Democratic Republic of Congo has worsened, with over 200 suspected deaths reported, and the virus now poses a risk to ten other African countries. Health organizations are intensifying efforts to contain the spread, while some countries implement screening and quarantine measures for travelers from affected regions.
The Ebola outbreak in DR Congo and Uganda is intensifying, leading to new cases, an attack on a treatment center, and international concerns such as flight diversions and event postponements. Health officials report hundreds of suspected cases and deaths as the virus spreads to new areas.
An opinion piece warns that recent Ebola and hantavirus outbreaks underscore the urgent need for better global pandemic preparedness. The World Health Organization also stated that an Ebola vaccine could take six to nine months to develop.
DW News. . The Democratic Republic of Congo has received more than 16,000 doses of the Ervebo Ebola vaccine as authorities intensify efforts to contain the country's largest-ever Ebola outbreak.
The Ebola epidemic in the Democratic Republic of Congo is spreading exponentially, with the death toll surpassing 2,500 people. The UN has warned that funds are running out in the fight against the disease, while the WHO has raised the risk level to 'very high'.
The Democratic Republic of Congo has received 70,000 doses of the Ervebo vaccine as the Bundibugyo Ebola outbreak continues to spread, aiming to curb the surge in infections.
Research has begun on a vaccine for the Bundibugyo strain of the Ebola virus. This comes as the Ebola epidemic in the Democratic Republic of Congo has become the deadliest in the country's history.
The Ebola epidemic in the Democratic Republic of Congo is on track to become the deadliest in history, with the World Health Organization warning that over 2,000 people have died.
The Ervebo vaccine has proven safe and effective against the common Zaire strain of the Ebola virus, with early data suggesting it may also protect against the rarer Bundibugyo strain, potentially leading to public availability in DR Congo.
The World Health Organization is appealing for more support to tackle the largest-ever Ebola outbreak in the Democratic Republic of Congo, which comes as Moderna has initiated its first Phase 1 clinical trial for an experimental mRNA vaccine targeting the Ebola variant responsible for the major outbreak.
The World Health Organization (WHO) announced that Hilleman Laboratories, a Singapore-based company, will undertake the development of what is considered the most promising vaccine for the Ebola virus.
A new vaccine targeting the Bundibugyo strain of the Ebola virus, which has been devastating the Democratic Republic of the Congo, has begun human clinical trials.
Oxford University has initiated the first human trials for a vaccine targeting the Bundibugyo strain of the Ebola virus. This comes as the majority of new Ebola cases in eastern Congo are from unknown chains, indicating the outbreak is outpacing the response.
A new Ebola vaccine developed by Oxford has begun its first human trial, with the Serum Institute of India committed to manufacturing over 620,000 doses.
A woman in Poland lost 100,000 PLN after falling victim to a scam where a caller, posing as a doctor, claimed a family member was infected with the Ebola virus and needed a 'specialized vaccine.'
Scientists are urgently working to develop a vaccine for the specific Ebola strain responsible for the current outbreak in the Democratic Republic of Congo. Research is underway to determine the effectiveness and readiness of various vaccine candidates.
The Democratic Republic of Congo has reopened the airport in Bunia, the epicenter of the current Ebola outbreak, as the World Health Organization reports over 300 confirmed cases and seeks more global support to contain the spreading disease.
Three new experimental vaccines are being urgently developed to combat a rare and rapidly spreading strain of Ebola in the Democratic Republic of Congo. International efforts are intensifying, with calls for immediate action and significant funding allocated to accelerate vaccine research.
The African Union has announced that a new vaccine specifically targeting the Bundibugyo strain of Ebola is expected to be available by the end of this year. This development offers significant hope in the fight against the deadly virus.
The World Health Organization has declared the Ebola risk in the Democratic Republic of Congo to be at its highest level, as the outbreak continues to spread rapidly. Health workers are struggling to contain the virus, prompting the UN to allocate $60 million and send additional personnel to the region.
An Ebola outbreak is causing increased concern due to a suspected undercount of cases. Meanwhile, the World Health Organization announced that an approved vaccine for the rare Bundibugyo strain is still several months from availability.
The World Health Organization is expediting the development and approval of two new Ebola vaccines in response to an outbreak in Central Africa, which has triggered a global emergency.
The Democratic Republic of Congo is grappling with an intensifying Ebola outbreak, characterized by a rare and rapidly spreading strain, a lack of medical supplies, and a rising number of suspected cases and deaths. International health organizations are concerned about the outbreak's growth and its impact, particularly on children.
